Abaloparatide-SC: Phase III data

Top-line data from the double-blind, international Phase III ACTIVE (Study BA058-05-003) trial in 2,463 postmenopausal women with severe osteoporosis showed that once-daily 80 µg abaloparatide-SC met the primary endpoint

Read the full 296 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE